TaiwanJ Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
TaiwanJ Pharmaceuticals has been growing earnings at an average annual rate of 12.3%, while the Biotechs industry saw earnings growing at 21.4% annually. Revenues have been declining at an average rate of 24.5% per year.
Key information
12.3%
Earnings growth rate
15.1%
EPS growth rate
Biotechs Industry Growth | 12.2% |
Revenue growth rate | -24.5% |
Return on equity | -48.4% |
Net Margin | n/a |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How TaiwanJ Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 0 | -28 | 16 | 16 |
31 Mar 24 | 11 | -17 | 16 | 15 |
31 Dec 23 | 23 | -6 | 15 | 14 |
30 Sep 23 | 30 | -38 | 20 | 12 |
30 Jun 23 | 38 | -71 | 25 | 10 |
31 Mar 23 | 27 | -82 | 25 | 11 |
31 Dec 22 | 15 | -92 | 24 | 13 |
30 Sep 22 | 8 | -60 | 18 | 15 |
30 Jun 22 | 1 | -27 | 12 | 17 |
31 Mar 22 | 11 | -20 | 13 | 17 |
31 Dec 21 | 22 | -12 | 14 | 18 |
30 Sep 21 | 22 | -14 | 14 | 19 |
30 Jun 21 | 22 | -15 | 15 | 20 |
31 Mar 21 | 11 | -29 | 15 | 23 |
31 Dec 20 | 0 | -42 | 14 | 26 |
30 Sep 20 | 0 | -47 | 16 | 34 |
30 Jun 20 | 0 | -51 | 17 | 42 |
31 Mar 20 | 31 | -28 | 20 | 34 |
31 Dec 19 | 62 | -5 | 22 | 26 |
30 Sep 19 | 62 | -76 | 21 | 29 |
30 Jun 19 | 62 | -147 | 21 | 31 |
31 Mar 19 | 31 | -193 | 20 | 61 |
31 Dec 18 | 0 | -238 | 20 | 91 |
30 Sep 18 | 0 | -195 | 20 | 112 |
30 Jun 18 | 0 | -152 | 20 | 132 |
31 Mar 18 | 0 | -169 | 21 | 149 |
31 Dec 17 | 0 | -186 | 21 | 166 |
30 Sep 17 | 0 | -210 | 22 | 191 |
30 Jun 17 | 0 | -234 | 24 | 215 |
31 Mar 17 | 0 | -228 | 25 | 209 |
31 Dec 16 | 0 | -223 | 25 | 202 |
30 Sep 16 | 0 | -199 | 25 | 182 |
30 Jun 16 | 0 | -176 | 25 | 161 |
31 Mar 16 | 0 | -159 | 24 | 146 |
31 Dec 15 | 0 | -142 | 22 | 132 |
30 Sep 15 | 0 | -128 | 24 | 109 |
30 Jun 15 | 0 | -114 | 25 | 87 |
31 Mar 15 | 0 | -106 | 24 | 80 |
31 Dec 14 | 0 | -98 | 23 | 73 |
Quality Earnings: 6549 is currently unprofitable.
Growing Profit Margin: 6549 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6549 is unprofitable, but has reduced losses over the past 5 years at a rate of 12.3% per year.
Accelerating Growth: Unable to compare 6549's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6549 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.8%).
Return on Equity
High ROE: 6549 has a negative Return on Equity (-48.39%), as it is currently unprofitable.